LongeVC’s Post

The FDA has approved Zurzuvae (zuranolone), the first and only oral treatment approved for women with postpartum depression: https://lnkd.in/dPy6ZYyN We hope that this will be another tool that can be effective in helping mothers who suffer from PPD. This is only the second drug developed to treat PPD, with the other being brexanolone (branded Zulresso), which is administered intravenously. Both zuranolone and brexanolone are synthetic versions of the same neurosteroid, allopregnanolone, which occurs naturally in the brain, made by the hormone progesterone. Read more CNN: https://lnkd.in/dUx7TRSa Thairath: https://lnkd.in/dVJCTqVd

The FDA has approved Zurzuvae (zuranolone), the first and only oral treatment approved for women with postpartum depression: https://lnkd.in/d8DHNfkm We hope that this will be another tool that can be effective in helping mothers who suffer from PPD. This is only the second drug developed to treat PPD, with the other being brexanolone (branded Zulresso), which is administered intravenously. Both zuranolone and brexanolone are synthetic versions of the same neurosteroid, allopregnanolone, which occurs naturally in the brain, made by the hormone progesterone. Read more CNN: https://lnkd.in/dKgS8wQ5 Thairath: https://lnkd.in/dGiXEdmF

🍄 Another breakthrough designation granted for psychedelic treatment 🍄 Following MindMed’s breakthrough designation for MM120 for GAD, Cybin Inc has also received breakthrough designation for their novel psilocybin compound, CYB003, as an adjunctive treatment for major depressive disorder! In their phase 2 trial, CYB003 significant mean reduction in MADRS scores of 22 points in both cohorts (12mg and 16mg). In the 16mg cohort, 75% of subjects achieved response (at least 50% improvement in MADRS scores). Remission was achieved in 60% of subjects in the 12mg cohort and 75% of subjects in the 16mg cohort! This improvement was durable at 4 months after baseline! Phase 3 trial is on the way and I can’t wait to see how things continue to progress.

Beckley Psytech reports positive results in the study of a #treatmentresistantdepression medication with 5-MeO-DMT (mebufotenin). The results of the 10 mg #BPL003 (#BeckleyPsytech) a chemically modified psychedelic in benzoate salt formulation were as measured by the Montgomery-Åsberg Depression Rating Scale *55% of patients with treatment-resistant depression responded rapidly to a single intranasal dose of BPL-003. * Depression remission persisted in 45% of patients at day 85. A hopeful result, the scope for new drug options for treatment-resistant depression. We wish you luck in the further development of this special substance

A large real-world study has provided evidence of associations between anti-VEGF drugs and various adverse events (AEs). These adverse events include ocular issues, cardiac disorders, and central nervous system problems. Read the full article here ⤵️ #retina #eyedisorders #nervoussystem

Conclusions: Intravenous racemic ketamine may be a better augmentative treatment for treatment-resistant unipolar depression than intranasal esketamine and aripiprazole. Whether intravenous racemic ketamine or lithium is superior is unclear currently. A larger head-to-head trial of intravenous racemic ketamine versus conventional augmentative treatments for treatment-resistant unipolar depression is needed.

Healthline: First-Ever Pill for Postpartum Depression Approved by FDA. What to Know The Food and Drug Administration (FDA) approved a first-of-its-kind drug to treat postpartum depression on August 4. The oral pill, Zurzuvae (zuranolone), has shown promise in clinical trials as a fast-acting treatment for postpartum depression (PPD), which occurs in 1 in 7 pregnanciesTrusted Source and often goes undetected during routine screenings. (Andrea Rice 08/07/2023) https://lnkd.in/eseJXd2T

Ready to discover the blueprint for patient-centric drug development in anxiety disorders? Explore the intersection of empathy and innovation in anxiety disorder research with Miami Clinical Research. Our latest blog post delves into the pivotal role patients play in shaping the future of drug development, offering hope and healing for those affected by anxiety. Learn more here: https://lnkd.in/gXAgkity #medicalresearch #clinicaltrials #medicalstudies #miamiclinicalresearch #anxiety #anxietydisorder #drugdevelopment #pharmaceuticalinnovation #clinicalresearch #anxietytreatment #anxietyresearch